Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study
| Autor: | Pēteris Alberts, Aina Muceniece, Ieva Strēle, Guna Proboka, Dite Venskus, Björn Jonsson, Jurgis Auziņš, Simona Doniņa |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Skin Neoplasms Side effect Adolescent Dermatology Young Adult Internal medicine medicine melanoma Humans Postoperative Period Virotherapy Child Survival analysis ECHO-7 virus Aged Neoplasm Staging Retrospective Studies Aged 80 and over Oncolytic Virotherapy Proportional hazards model business.industry Melanoma Hazard ratio Retrospective cohort study immunomodulator Middle Aged medicine.disease ORIGINAL ARTICLES: Clinical research Combined Modality Therapy Latvia Survival Analysis Oncolytic virus Surgery Enterovirus B Human oncolytic Child Preschool Female immunotherapy virotherapy business |
| Zdroj: | Melanoma Research |
| ISSN: | 1473-5636 |
| Popis: | An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004. The present retrospective study was carried out to determine the effectiveness of Rigvir in substage IB, IIA, IIB and IIC melanoma patients on time to progression and overall survival. White patients (N=79) who had undergone surgical excision of the primary melanoma tumour were included in this study. All patients were free from disease after surgery and classified into substages IB, IIA, IIB and IIC. Circulating levels of clinical chemistry parameters were recorded. Survival was analysed by Cox regression. Rigvir significantly (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|